Florent Gros

Biography

 Dr. Florent Gros has been the Managing Director of Novartis Venture Funds since January 2007. Dr. Gros serves as an Investor Director of Opsona Therapeutics Limited. For 20 years, Dr. Gros held various positions and projects in the intellectual property, transaction matters and venture areas at Nestlé, Aventis-Pasteur, Pasteur Merieux Connaught (Sanofi Pasteur), and Novartis in various countries including Switzerland, France and U.S.A. He serves as a Director of AIT, Adicet Bio, Inc., Vaxin, Inc., Anokion SA, Kanyos Bio, Inc., Inflazome Ltd., MyoPowers Medical Technologies France SAS (alternate name, MyoPowers Medical Technologies SA), Atlas Genetics, Applied Immune TherapeuticsNanoPowers AG, Evolva AG, Nabriva Therapeutics Forschungs GmbH and Okairos AG. He serves as a Director of Vivet Therapeutics. Dr. Gros served as a Member of Supervisory Board and Director of Merus B.V. since January 2010. He served as a Director of Opsona Therapeutics Limited since February 18, 2009 and GenSight Biologics SA since April 8, 2013 until July 2016. He served as a Director of Altimmune, Inc. until September 13, 2016. He served as a Director of Immune Targeting Systems (ITS) Limited. He served as a Director of Cellerix, S.A. and NeoVacs S.A. Dr. Gros is a Kaufmann Fellow (class 12), Biotechnology Engineering Master Degree from France and made his Diploma thesis at Glaxo-Vaccine in Belgium. He also holds European and French Patent Lawyer degrees and a Master degree in Private Law.

Research Interest

 Investor,  intellectual property, transaction matters